Clinical Trials for Multiple Myeloma

201808202

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) Phase III Principal Investigator Vij, Ravi…

201809141

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within one year…

201907148

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma Phase II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn…

202001061

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and…

201102270

Tissue Acquisition for Genomic and Proteomic Analysis of Plasma Cell Dyscrasias Phase N/A Principal Investigator Vij, Ravi Disease Site Multiple Myeloma

201509025

Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies Phase N/A Principal Investigator Vij, Ravi Disease Site Multiple Myeloma

201701084

A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) with Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Phase II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study…

201808202

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of bb2121 versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) Phase III Principal Investigator Vij, Ravi…

201809141

A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within one year…

201810124

A PHASE 1 STUDY OF FOR46 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) Phase I Principal Investigator Schroeder, Mark Disease Site Multiple Myeloma Learn more about this study at:…

201901003

Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen) Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study…

201905012

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma Phase I Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about…

201907148

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma Phase II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn…

201907150

Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY) Phase III…

201910168

A phase I study of human placental hematopoietic stem cell derived natural killer cells (CYNK-001) in multiple myeloma patients following autologous stem cell transplant in the front-line setting. Phase I/II (Cancer Control) Principal Investigator Vij,…

201910194

A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

201910200

Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma Phase II Principal Investigator Schroeder, Mark Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

201911061

A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and Anti-TIGIT (BMS-986207) Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

201911163

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) Phase III Principal Investigator Stockerl-Goldstein, Keith Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

202001061

A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and…

202009027

A Phase 1 Study of ION251 Administered by Intravenous Infusion to Patients with Relapsed/Refractory Multiple Myeloma Phase I Principal Investigator Stockerl-Goldstein, Keith Disease Site Multiple Myeloma Learn more about this study at: clinicaltrials.gov

202012040

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma Phase I/II Principal Investigator Vij, Ravi Disease Site Multiple Myeloma…

202103090

An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patients with Relapsed or Refractory Multiple Myeloma Phase I Principal Investigator Vij, Ravi Disease Site Multiple Myeloma Learn more about…